Physician profile
Anastasios Manaris
NPI 1104806561
$10,698.73
in general payments reported to CMS, 2019-2025
27 companies · $2,033 in 2025
The $2,033 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $1,026 · 2021: $1,466 · 2022: $1,619 · 2023: $1,471 · 2024: $1,736 · 2025: $2,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,970 · Travel and Lodging: $252 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,969.66 |
| Travel and Lodging | $251.92 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,096.62 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Resonate El Icd Vr, Varithena Administration Pack |
| Abbott Laboratories | $1,945.03 | 2019-2025 | Aveir, Jot Dx, Cardiomems |
| Biotronik INC. | $1,157.67 | 2019-2024 | Selectra |
| Medtronic, INC. | $1,122.79 | 2021-2025 | Selectsecure, Azure Xt Dr Mri Surescan, Venaseal |
| Elutia, INC. | $842.31 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $600.19 | 2022-2024 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.47 | 2021-2025 | Jardiance |
| Amgen INC. | $360.45 | 2021-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $228.39 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $218.39 | 2021-2024 | Optimizer |
| Lilly USA, LLC | $216.74 | 2021-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.59 | 2021-2022 | |
| Medtronic Vascular, INC. | $192.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $190.70 | 2019-2023 | Xarelto |
| Heartflow, INC. | $148.32 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $147.04 | 2020-2022 | |
| Inspire Medical Systems, INC. | $127.95 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $103.82 | 2019-2023 | |
| Edwards Lifesciences Corporation | $75.18 | 2019 | |
| Pfizer INC. | $41.66 | 2019-2022 | |
| Philips North America LLC | $34.09 | 2020-2023 | |
| Cvrx, INC. | $29.67 | 2024 | Barostim Neo System |
| Biosense Webster, INC. | $29.34 | 2023 | Octaray Mapping Catheter |
| Infobionic, INC | $23.51 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $20.04 | 2025 | Rhythm Express |
| Scpharmaceuticals INC. | $15.88 | 2025 | |
| Preventice Services, LLC | $15.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anastasios Manaris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.